Teva Pharmaceutical Industries Investor Presentation — July 2024

Document content

July 31, 2024Second Quarter 2024

ResultsTeva Pharmaceutical Industries Ltd.2|This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, bo th known

and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward -looking statements. Important factors that could cause or contribute to such differences include risks rela ting to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic product s; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products;

our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional

pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether

organically or through business development, and to sustain and focus our portfolio of generics medicines; and the effectiven essof our patents and other measures to protect our intellectual property rights, including any potential challenges to our Oran ge

Book patent listings in the U.S.;

• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions ormake new investments, may result in a future downgrade of our credit ratings; and our inability to raise debt or borrow funds in

amounts or on terms that are favorable to us;

• our business and operations in general, including: the impact of global economic conditions and other macroeconomic developme ntsand the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable

disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrat e and retain highly skilled personnel; interruptions in our supply chain or problems with internal or third party manufacturing; disruptions

of information technology systems; breaches of our data security; challenges associated with conducting business globally, in cluding political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukrai ne and

the state of war declared in Israel; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integ rate